Chair: Paul Hastings, President & CEO, OncoMed Pharmaceuticals, Inc.
Staff Contact: Frederick Bittenbender, Executive Vice President, Public Affairs, fbittenbender(at)bio.org
Description: The committee oversees BIO’s Alliance Development initiatives and strategic engagement with third party stakeholders including patient advocacy, provider, and other organizations committed to ensuring the development of and access to innovative therapies.
Adrian Adams, President & CEO, Auxilium Pharmaceuticals, Inc.
Alex Azar, President, Eli Lilly, USA
Allen Waxman, SVP & General Counsel, Eisai, Inc.
Arlene Morris, Chief Executive Officer, Syndax Pharmaceuticals, Inc.
Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics, Inc.
Christi Shaw, US Country President, Novartis
David Meeker, Chief Executive Officer, Genzyme Corporation: A Sanofi Company
David Stack, President & CEO, Pacira Pharmaceuticals, Inc.
H. Thomas Watkins, Chair Emeritus,BIO
Hans Schikan, Chief Executive Officer, Prosensa, Inc.
Jay Siegel, Chief Biotechnology Officer & Head of Scientific Strategy & Policy, Johnson and Johnson
Jeffrey Hatfield, Chief Executive Officer, Vitae Pharmaceuticals, Inc.
Jeffrey Wren, SVP, President North American Region, UCB
John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
Julie Gerberding, President, Merck Vaccines, Merck, Inc.
Kristine Peterson, Chief Executive Officer, Valeritas, Inc.
Michelle Dipp, Chief Executive Officer, Ovascience, Inc.
Neil Warma, President & CEO, Opexa Therapeutics, Inc.
Nick Leschly, President & CEO, bluebird bio
Rachel King, Chief Executive Officer, GlycoMimetics, Inc.
R. John Glasspool, VP, New Therapies & Market Development, Baxter Healthcare Corporation
Raymond Sacchetti, SVP, U.S. Access & Government Affairs, Bristol-Myers Squibb Company
Richard Pops, Chairman & CEO, Alkermes, plc
Ron Cohen, President & CEO, Acorda Therapeutics, Inc.
Stuart Arbuckle, EVP & Chief Commercial Officer, Vertex Pharmaceuticals Incorporated